ActRIIA antag 
Welcome,         Profile    Billing    Logout  
 8 Companies  5 Products   5 Products   36 Diseases   19 Trials   818 News 
25 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bimagrumab (BYM338) / Eli Lilly
2016-004124-26: Safety, pharmacokinetics and efficacy of bimagrumab in overweight and obese patients with type 2 diabetes

Not yet recruiting
2
68
Europe
bimagrumab, BYM338, Concentrate for solution for infusion
Novartis Pharma AG, Novartis Pharma AG
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 2, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
NCT06643728: A Study to Investigate Weight Management with Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults with Obesity or Overweight

Recruiting
2
240
US
Bimagrumab, LY3985863, BYM338, VER201, Tirzepatide, LY3298176, Bimagrumab Placebo, Tirzepatide Placebo
Eli Lilly and Company
Obesity, Overweight
04/26
01/27
NCT06901349: A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants with Obesity or Overweight with Type 2 Diabetes

Not yet recruiting
2
180
Canada, Japan, US, RoW
Bimagrumab, LY3985863, Tirzepatide, LY3298176, Bimagrumab Placebo, Tirzepatide Placebo
Eli Lilly and Company
Obesity, Overweight
10/26
01/27
NCT05616013: Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

Active, not recruiting
2
507
US, RoW
Bimagrumab, Semaglutide, Wegovy, Ozempic, Bimagrumab Placebo
Eli Lilly and Company, Versanis Bio, Inc.
Obesity, Obese, Overweight or Obesity
05/24
06/25
NCT05933499: Effect of Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults with Obesity

Not yet recruiting
2
65
NA
IV bimagrumab, IV placebo, Semaglutide, Calcium/Vitamin D, Lifestyle and nutrition counseling
Massachusetts General Hospital
Obesity
07/28
07/28
NCT06890611: A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

Not yet recruiting
1
100
US
Bimagrumab, LY3985863, BYM338, VER201, Tirzepatide, LY3298176, Bimagrumab + Tirzepatide Coformulation, LY900042
Eli Lilly and Company
Healthy
11/25
11/25
Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
NCT06409026: Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension

Recruiting
4
21
US
Sotatercept
Mayo Clinic
Pulmonary Arterial Hypertension
03/26
03/26
RECOMPENSE, NCT06658522: Right Ventricular Compensation with Sotatercept: a Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension

Not yet recruiting
4
20
NA
Sotatercept
Amsterdam UMC, location VUmc, MSD Nederland BV
Pulmonary Arterial Hypertension PAH, Pulmonary Arterial Hypertension WHO Group I, Pulmonary Arterial Hypertension
10/26
10/26
2021-001498-21: A study to evaluate Sotatercept in Participants with PAH WHO FC III or FC IV at High Risk of Mortality Estudio para evaluar sotatercept en pacientes con HAP con una CF de la OMS III o IV y riesgo elevado de mortalidad

Not yet recruiting
3
166
Europe
Sotatercept, ACE-011, Lyophilisate for solution for injection
Acceleron Pharma Inc., ACCELERON PHARMA INC., Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Acceleron Pharma Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Acceleron Pharma Inc., Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Acceleron Pharma Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Pulmonary Arterial Hypertension (PAH) Hipertensión Arterial Pulmonar (HAP), Cardiovascular Disease Enfermedad Cardiovascular, Diseases [C] - Cardiovascular Diseases [C14]
 
 
MK-7962-020, NCT05818137: A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants

Active, not recruiting
3
46
Japan
Sotatercept, MK-7962, ActRIIA-IgG1Fc, ACE-011
Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
03/24
08/25
ZENITH, NCT04896008: A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/)

Completed
3
172
Europe, Canada, US, RoW
Sotatercept, MK-7962, ACE-011, Placebo
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Arterial Hypertension
07/24
02/25
SOTERIA, NCT04796337 / 2020-005061-13: A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12)

Recruiting
3
700
Europe, Canada, US, RoW
Sotatercept, ACE-011, MK-7962
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Arterial Hypertension, PAH
02/31
02/31
HYPERION, NCT04811092 / 2021-000199-12: Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)

Active, not recruiting
3
444
Europe, Canada, US, RoW
Sotatercept, MK-7962, ACE-011, Placebo
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Arterial Hypertension
04/25
04/25
2022-000478-25: Sotatercept in Children with Pulmonary Artery Hypertension on Standard of Care

Ongoing
2
42
Europe
Sotatercept, MK-7962, Lyophilisate for solution for injection
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Pulmonary arterial hypertension, Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure (hypertension) in the arteries of the lungs, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2021-003020-32: A Phase 2 Study of Sotatercept for Combined Postcapillary and Precapillary Pulmonary Hypertension Treatment

Not yet recruiting
2
180
Europe
Sotatercept, ACE-011 / MK-7962, Lyophilisate for solution for injection
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Acceleron Pharma Inc., ACCELERON PHARMA INC., Acceleron Pharma Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Acceleron Pharma Inc., Acceleron Pharma Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved EjectionFraction (HFpEF), Combined Postcapillary and Precapillary Pulmonary Hypertension due to Heart Failure, Diseases [C] - Cardiovascular Diseases [C14]
 
 
CADENCE, NCT04945460: A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

Active, not recruiting
2
150
Europe, Canada, US, RoW
Sotatercept 0.3 mg/kg, ACE-011, Placebo, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Hypertension, Pulmonary
09/25
09/25
LIGHTRAY, NCT06664801: A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

Recruiting
2
160
Europe, Canada, Japan, US, RoW
Sotatercept, MK-7962, Background PAH Therapy
Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
07/26
07/26
HARMONIZE, NCT06814145: Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

Not yet recruiting
2
130
NA
Sotatercept, ACE-011
Merck Sharp & Dohme LLC
Hypertension, Pulmonary
03/29
03/29
Sox-PH, NCT06351345: 129 Xenon Imaging in Patients Treated with Sotatercept

Not yet recruiting
2
14
US
129Xe Hyperpolarized
Bastiaan Driehuys, Merck Sharp & Dohme LLC
Pulmonary Hypertension, Pulmonary Arterial Hypertension
08/26
08/26
MOONBEAM, NCT05587712 / 2022-000478-25: Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

Recruiting
2
42
Europe, US, RoW
Sotatercept, MK-7962
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
09/28
09/28
NCT01562405: Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Active, not recruiting
1
33
US
ACE-011, Sotatercept, Lenalidomide, Revlimid, Dexamethasone, Decadron, Pomalidomide, Pomalyst
Massachusetts General Hospital, Multiple Myeloma Research Consortium
Multiple Myeloma
12/24
06/25
NCT06843460: A Clinical Study of MK-7962 in Healthy Chinese Participants (MK-7962-021)

Completed
1
24
RoW
Sotatercept, MK-7962, ActRIIA-IgG1Fc, ACE-011, Placebo
Merck Sharp & Dohme LLC
Healthy
05/24
05/24
NCT03724227: Expanded Access for ACE-011

No Longer Available
N/A
US
ACE-011, Sotatercept
Celgene
Myelodysplastic Syndrome
 
 
NCT06751082: Real World Observational Study of Sotatercept for Pulmonary Hypertension

Enrolling by invitation
N/A
120
US
Mayo Clinic
Pulmonary Hypertension
01/35
01/35
BIIB110 / Biogen
ACTRN12623000204640: A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ALG-801 in Healthy Postmenopausal Women

Completed
1
32
 
AliveGen USA, Inc., AliveGen USA, Inc.
Bone loss, Muscle wasting
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bimagrumab (BYM338) / Eli Lilly
2016-004124-26: Safety, pharmacokinetics and efficacy of bimagrumab in overweight and obese patients with type 2 diabetes

Not yet recruiting
2
68
Europe
bimagrumab, BYM338, Concentrate for solution for infusion
Novartis Pharma AG, Novartis Pharma AG
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 2, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
NCT06643728: A Study to Investigate Weight Management with Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults with Obesity or Overweight

Recruiting
2
240
US
Bimagrumab, LY3985863, BYM338, VER201, Tirzepatide, LY3298176, Bimagrumab Placebo, Tirzepatide Placebo
Eli Lilly and Company
Obesity, Overweight
04/26
01/27
NCT06901349: A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants with Obesity or Overweight with Type 2 Diabetes

Not yet recruiting
2
180
Canada, Japan, US, RoW
Bimagrumab, LY3985863, Tirzepatide, LY3298176, Bimagrumab Placebo, Tirzepatide Placebo
Eli Lilly and Company
Obesity, Overweight
10/26
01/27
NCT05616013: Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

Active, not recruiting
2
507
US, RoW
Bimagrumab, Semaglutide, Wegovy, Ozempic, Bimagrumab Placebo
Eli Lilly and Company, Versanis Bio, Inc.
Obesity, Obese, Overweight or Obesity
05/24
06/25
NCT05933499: Effect of Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults with Obesity

Not yet recruiting
2
65
NA
IV bimagrumab, IV placebo, Semaglutide, Calcium/Vitamin D, Lifestyle and nutrition counseling
Massachusetts General Hospital
Obesity
07/28
07/28
NCT06890611: A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

Not yet recruiting
1
100
US
Bimagrumab, LY3985863, BYM338, VER201, Tirzepatide, LY3298176, Bimagrumab + Tirzepatide Coformulation, LY900042
Eli Lilly and Company
Healthy
11/25
11/25
Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
NCT06409026: Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension

Recruiting
4
21
US
Sotatercept
Mayo Clinic
Pulmonary Arterial Hypertension
03/26
03/26
RECOMPENSE, NCT06658522: Right Ventricular Compensation with Sotatercept: a Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension

Not yet recruiting
4
20
NA
Sotatercept
Amsterdam UMC, location VUmc, MSD Nederland BV
Pulmonary Arterial Hypertension PAH, Pulmonary Arterial Hypertension WHO Group I, Pulmonary Arterial Hypertension
10/26
10/26
2021-001498-21: A study to evaluate Sotatercept in Participants with PAH WHO FC III or FC IV at High Risk of Mortality Estudio para evaluar sotatercept en pacientes con HAP con una CF de la OMS III o IV y riesgo elevado de mortalidad

Not yet recruiting
3
166
Europe
Sotatercept, ACE-011, Lyophilisate for solution for injection
Acceleron Pharma Inc., ACCELERON PHARMA INC., Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Acceleron Pharma Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Acceleron Pharma Inc., Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Acceleron Pharma Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Pulmonary Arterial Hypertension (PAH) Hipertensión Arterial Pulmonar (HAP), Cardiovascular Disease Enfermedad Cardiovascular, Diseases [C] - Cardiovascular Diseases [C14]
 
 
MK-7962-020, NCT05818137: A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants

Active, not recruiting
3
46
Japan
Sotatercept, MK-7962, ActRIIA-IgG1Fc, ACE-011
Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
03/24
08/25
ZENITH, NCT04896008: A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/)

Completed
3
172
Europe, Canada, US, RoW
Sotatercept, MK-7962, ACE-011, Placebo
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Arterial Hypertension
07/24
02/25
SOTERIA, NCT04796337 / 2020-005061-13: A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12)

Recruiting
3
700
Europe, Canada, US, RoW
Sotatercept, ACE-011, MK-7962
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Arterial Hypertension, PAH
02/31
02/31
HYPERION, NCT04811092 / 2021-000199-12: Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)

Active, not recruiting
3
444
Europe, Canada, US, RoW
Sotatercept, MK-7962, ACE-011, Placebo
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Arterial Hypertension
04/25
04/25
2022-000478-25: Sotatercept in Children with Pulmonary Artery Hypertension on Standard of Care

Ongoing
2
42
Europe
Sotatercept, MK-7962, Lyophilisate for solution for injection
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Pulmonary arterial hypertension, Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure (hypertension) in the arteries of the lungs, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2021-003020-32: A Phase 2 Study of Sotatercept for Combined Postcapillary and Precapillary Pulmonary Hypertension Treatment

Not yet recruiting
2
180
Europe
Sotatercept, ACE-011 / MK-7962, Lyophilisate for solution for injection
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Acceleron Pharma Inc., ACCELERON PHARMA INC., Acceleron Pharma Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Acceleron Pharma Inc., Acceleron Pharma Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved EjectionFraction (HFpEF), Combined Postcapillary and Precapillary Pulmonary Hypertension due to Heart Failure, Diseases [C] - Cardiovascular Diseases [C14]
 
 
CADENCE, NCT04945460: A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

Active, not recruiting
2
150
Europe, Canada, US, RoW
Sotatercept 0.3 mg/kg, ACE-011, Placebo, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Hypertension, Pulmonary
09/25
09/25
LIGHTRAY, NCT06664801: A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

Recruiting
2
160
Europe, Canada, Japan, US, RoW
Sotatercept, MK-7962, Background PAH Therapy
Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
07/26
07/26
HARMONIZE, NCT06814145: Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

Not yet recruiting
2
130
NA
Sotatercept, ACE-011
Merck Sharp & Dohme LLC
Hypertension, Pulmonary
03/29
03/29
Sox-PH, NCT06351345: 129 Xenon Imaging in Patients Treated with Sotatercept

Not yet recruiting
2
14
US
129Xe Hyperpolarized
Bastiaan Driehuys, Merck Sharp & Dohme LLC
Pulmonary Hypertension, Pulmonary Arterial Hypertension
08/26
08/26
MOONBEAM, NCT05587712 / 2022-000478-25: Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

Recruiting
2
42
Europe, US, RoW
Sotatercept, MK-7962
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
09/28
09/28
NCT01562405: Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Active, not recruiting
1
33
US
ACE-011, Sotatercept, Lenalidomide, Revlimid, Dexamethasone, Decadron, Pomalidomide, Pomalyst
Massachusetts General Hospital, Multiple Myeloma Research Consortium
Multiple Myeloma
12/24
06/25
NCT06843460: A Clinical Study of MK-7962 in Healthy Chinese Participants (MK-7962-021)

Completed
1
24
RoW
Sotatercept, MK-7962, ActRIIA-IgG1Fc, ACE-011, Placebo
Merck Sharp & Dohme LLC
Healthy
05/24
05/24
NCT03724227: Expanded Access for ACE-011

No Longer Available
N/A
US
ACE-011, Sotatercept
Celgene
Myelodysplastic Syndrome
 
 
NCT06751082: Real World Observational Study of Sotatercept for Pulmonary Hypertension

Enrolling by invitation
N/A
120
US
Mayo Clinic
Pulmonary Hypertension
01/35
01/35
BIIB110 / Biogen
ACTRN12623000204640: A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ALG-801 in Healthy Postmenopausal Women

Completed
1
32
 
AliveGen USA, Inc., AliveGen USA, Inc.
Bone loss, Muscle wasting
 
 

Download Options